The role of high-dose intravenous immunoglobulin in rheumatology

Rheumatology

Volumn 49, Issue 6, 2010, Pages 1040-1048

  Vaitla, Prashantha M ^a   McDermott, Elizabeth M ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Anti phospholipid syndrome; Dermatomyositis; Immunoglobulin; IVIG; Juvenile idiopathic arthritis; Kawasaki disease; Polymyositis; Systemic lupus erythematosus; Therapy; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HEPARIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE;

ACUTE KIDNEY FAILURE; ADAPTIVE IMMUNITY; ADD ON THERAPY; ANCA ASSOCIATED VASCULITIS; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ASEPTIC MENINGITIS; BEHCET DISEASE; CHURG STRAUSS SYNDROME; DERMATOMYOSITIS; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FATIGUE; HUMAN; IMMUNOMODULATION; JUVENILE RHEUMATOID ARTHRITIS; KIKUCHI DISEASE; LOW DRUG DOSE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; POLYMYOSITIS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

AUTOIMMUNE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 77953492376     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq021     Document Type: Review

References (74)

1. Centres for disease control and prevention. Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994;43:505-9.
2. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypo-gammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
3. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005;142: 1-11.
4. Pyne D, Eherstein M, Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 2002;41:367-74.
5. Leong H, Stachnik J, Bonk ME, Matuszewski KA. Unlabelled uses of intravenous immunoglobulin. Am J Health Syst Pharm 2008;65:1815-24.
6. Department of Health.http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085237.
7. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the toes and fingers in children. Jpn J Allerg 1967;16:178-222.
8. Oates-Whitehead R, Baumer J, Haines L et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database systemic Rev 2003;4: CD0040000.
9. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.
10. Burns JC, Best BM, Mejias A et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008;153:833-8.
11. Lee HK, Kim DS, Noh GW, Lee KY. Effects of immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease. Yonsei Med J 1996;37:357-63.
12. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis-four year review of nine cases. Arch Dis Child 1995;72:25-8.
13. Tsai MJ, Lai CC, Lin SC, Chiang BL, Chou CC, Hsieh KH. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1997;38:111-5.
14. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000;27:2498-503.
15. Permal S, Wechsler B, Cabane J, Perrot S, Blum L, Imbert JC. Treatment of stills disease in adults with intravenous immunoglobins. Rev Med Interne 1995;16:250-4.
16. Vignes S, Wechsler B, Amoura Z et al. Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998;16:295-8.
17. Prieur AM, Adleff A, Debre M, Boulate P, Griscelli C. High dose immunoglobulin therapy in severe juvenile chronic arthritis: longterm follow up in 16 patients. Clin Exp Rheumatol 1990;8:603-8.
18. Uzeil Y, Laxer RM, Schneider R, Silverman ED. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J Rheumatol 1996;23:910-8.
19. Silverman ED, Laxer RM, Greenwald M et al. Intravenous immunoglobulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1990;33:1015-22.
20. Silverman ED, Cawkwell GD, Lovell DJ et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomised placebo controlled trial. J Rheumatol 1994;21:2353-8.
21. Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serological response. Lupus 1999;8:705-12.
22. Sherer Y, Kuechler S, Jose Scali J et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 2008;10: 55-7.
23. Micheloud D, Calderon M, Caparrros M, D'Cruz DP. Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann Rheum Dis 2007;66:986-7.
24. Grenader T, Shavit L. Intravenous immunoglobulin in treatment of cardiac tamponade in a patient with systemic lupus erythematosus. Clin Rheumatol 2004;23:530-2.
25. Becker BN, Fuchs H, Hakim R. Intravenous immunoglobulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. J Am Soc Nephrol 1995;5:1746-50.
26. Lazurova I, Macejova Z, Benhatchi K et al. Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea. Clin Rheumatol 2007;26:2145-7.
27. Lesprit P, Mouloud F, Bierling P et al. Prolonged remission of SLE-associated polyradiculoneuropathy after a single course of intravenous immunoglobulin. Scand J Rheumatol 1996;25:177-9.
28. Milstone AM, Meyers K, Elia J. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol 2005;24:394-7.
29. Aharon A, Levy Y, Bar-Dayan Y et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997;6:408-11.
30. Chetan G, Mahadevan S, Sulanthung K, Narayanan P. Intravenous immunoglobulin therapy of lupus pneumonitis. Indian J Pediatr 2007;74:1032-3.
31. Arnal C, Piette JC, Leone J et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002;29: 75-83.
32. Levy Y, Sherer Y, George G, Rovensky J, Lukac J, Ravora L. Intravenous immunoglobulin treatment of lupus nepritis. Semin Arthritis Rheum 2000;29:321-7.
33. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long-term IVIG treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:163-8.
34. Boletis JN, Ioannidis JP, Boki KA, Moutsoupoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999;354:569-70.
35. Hashkes PJ, Lovell DJ. Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 1996;14:673-5.
36. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high dose immune globulin infusions as treatment for dermatomyositis. N Eng J Med 1993;329:1993-2000.
37. Cherin P, Herson S. Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins. Ann Med Interne 1993;144: 521-5.
38. Cherin P, Pelletier S, Teixeira A et al. Results and longterm followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002;46:467-74.
39. Danieli MG, Malcangi G, Palmieri C et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002;61: 37-41.
40. Cherin P, Piette JC, Welchsler B et al. Intravenous immunoglobulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adults. J Rheumatol 1994;21:1092-7.
41. Nacci F, Righi A, Conforti ML et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007;66:977-9.
42. Amital H, Rewald E, Levy Y et al. Fibrosis regression induced by intravenous immunoglobulin treatment. Ann Rheum Dis 2003;62:175-7.
43. Levy Y, Amital H, Langevitz P et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open study. Arthritis Rheum 2004;50:1005-7.
44. Lockwood CM. New treatment strategies for systemic vasculitis: the role of intravenous immunoglobulin therapy. Clin Exp Immunol 1996;104:77-82.
45. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000;93:433-9.
46. Martinez V, Cohen P, Pagnoux C et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic antibodies. Arthritis Rheum 2008;58:308-17.
47. Langford CA, Hoffman GS. Intravenous immunoglobulin in Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum 2008;58:2211-2.
48. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996; 35:1150-3.
49. Jayne DR, Esnault VL, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993;6: 207-19.
50. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995;101:2-7.
51. Levy Y, Sherer Y, George J et al. Serological and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999;119: 231-8.
52. Hamilos DL, Christensen J. Treatment of Churg-Strauss syndrome with high dose intravenous immunoglobulin. J Allergy Clin Immunol 1991;88:823-4.
53. Tsurikisawa N, Taniguchi M, Saito H et al. Treatment of Churg-Strauss syndrome with high dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004;92: 80-7.
54. Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Longterm effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004;63:1649-54.
55. Heldrich FJ, Minkin S, Gatdula CL. Intravenous immunoglobulin in Henoch-Schonlein purpura: a case study. Md Med J 1993;42:577-9.
56. Fagbemi AA, Torrente F, Hilson AJ, Heuschkel RB, Murch SH. Massive gastrointestinal hemorrhage in isolated intestinal Henoch-Schonlein purpura with response to intravenous immunoglobulin infusion. Eur J Pediatr 2007;166:915-9.
57. Blanco R, Gonzalez-Gay MA, Ibanez D, Sanchez-Andrade A, Gonzalez-Vela C. Paradoxical and persistent renal impairment in Henoch-Schonlein purpura after high-dose immunoglobulin therapy. Nephron 1997; 76:247-8.
58. Carreras LO, Perez GN, Vega HR, Casavilla F. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet 1988;2:393-4.
59. Branch DW, Peaceman AM, Druzin M et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000;182:122-7.
60. Jeremic K, Pervulov M, Gojnic M, Dukanac J, Ljubic A, Stojnic J. Comparison of two therapeutic protocols in patients with antiphospholipid antibodies and recurrent miscarriages. Vojnosanit Pregl 2005;62:435-9.
61. Triolo G, Ferrante A, Ciccia F et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003;48:728-31.
62. Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid syndrome. Int J Gynaecol Obstet 2009; 104:223-5.
63. Perricone R, De Carolis C, Kroegler B et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology 2008;47:646-51.
64. Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 2008;34: 290-4.
65. Emery P, Spath P, Affentranger P, Schwarz HA, Gough A. A placebo controlled double blind study of high dose intravenous immunoglobulin therapy in patients with early rheumatoid arthritis [abstract]. Arthritis Rheum 1996;39: 1027-9.
66. Kanik KS, Yarboro CH, Naparstek Y, Plotz PH, Wilder RL. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum 1996;39:1027-9.
67. Zeuner RA, Schroeder JO, Schröder F, Euler HH. Successful application of high dose intravenous immunoglobulins in Sjögren's syndrome associated arthritis. Ann Rheum Dis 1995;54:936.
68. Durez P, Tourné L, Feremans W, Mascart-Lemone F, Heenen M, Appelboom T. Dramatic response to intrave-nous high dose gamma-globulin in refractory vasculitis of the skin associated with Sjögren's syndrome. J Rheumatol 1998;25:1032-3.
69. Wakasugi D, Kato T, Gono T et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren's syndrome. Mod Rheumatol 2009; 19:437-40.
70. Morozumi S, Kawagashira Y, Iijima M et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome. J Neurol Sci 2009; 279:57-61.
71. Rajabally YA, Seow H, Abbott RJ. Immunoglobulin-responsive dysautonomia in Sjögren's syndrome. J Neurol 2007;254:674-5.
72. Nir S, Itzchak B, Jehudith S, Benjamin M. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol 2001;85:1287-8.
73. Kaaja R, Julkunen H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. Arthritis Rheum 2003;48: 280-2.
74. Noursadeghi M, Aqel N, Gibson P, Pasvol G. Successful treatment of Kikuchi's disease with intravenous immunoglobulin. Rheumatology 2006;45: 235-7.